Protocol Ledger

Academic / Cooperative Group · Consolidated Sponsor Hub

Dana-Farber Cancer Institute: Clinical Trials & FDA Approval Profile

Dana-Farber Cancer Institute (Boston, MA) sponsors 93 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 56 active protocols (29 recruiting now), 17 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)21.5%
Median Closed Enrollment vs National (145 pts)23 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Dana-Farber Cancer Institute
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)93
Active Pipeline (Recruiting Now)56 (29)
Completed vs Stopped Early17 / 20 (21.5%)
Median Closed Actual Enrollment23 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Dana-Farber Cancer Institute
Hospital Research SiteLocationShared Protocols
Dana-Farber Cancer InstituteBoston, MA85
Brigham and Women's HospitalBoston, MA26
Beth Israel Deaconess Medical CenterBoston, MA25

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Dana-Farber Cancer Institute
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04893109ATEMPT 2.0: Adjuvant T-DM1 vs THPhase IIRECRUITING
NCT04620187Post-op T-DM1 in HER-2+ Salivary Gland CarcinomasPhase IIRECRUITING
NCT04468061Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBCPhase IIRECRUITING
NCT03587740ATOP TRIAL: T-DM1 in HER2 Positive Breast CancerPhase IIACTIVE NOT RECRUITING
NCT04569747A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-pPhase IIACTIVE NOT RECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Dana-Farber Cancer Institute across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Dana-Farber Cancer Institute Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI